Co-pay funding is provided only by pharmaceutical and biotechnology companies. LLS’s co-pay assistance program is handled separately from funds donated by individuals, companies and foundations. Donors to LLS can be assured that their funding is supporting LLS’s full and robust agenda for patients, including breakthrough research as well as support that is helping patients every day, as they deal with diagnosis and treatment. LLS dedicates a significant portion of its donated funds to helping patients, including free education and information, help to find clinical trials testing new treatments, and more. We have disbursed more than $393 million in total to more than 89,000 blood cancer patients participating in all of our co-pay funds. We have disbursed nearly $114 million to lymphoma patients in assistance over that time, with $12 million in fiscal year 2018 to date. LLS’s co-pay assistance program has helped more than 37,000 lymphoma patients since its inception in 2007. Our goal is to provide assistance to patients in need and we are making every effort to obtain additional funding to reopen the lymphoma fund. As a patients first organization we believe that our co-pay assistance programs are an important way for us to help blood cancer patients and their families. This situation underscores the ever-growing financial burden that cancer patients and their families are facing.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |